In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|October 29, 2021
Expert: How Targeted Medication Safety Best Practices Impacts Pharmacy Technicians
Author(s)Ashley Gallagher, Editor
Emily Holcomb, PharmD, BCPS, ISMP Safe Medication Management Fellow, discusses her CPhT 2021 conference presentation regarding targeted medication safety best practices.
Advertisement
In a Pharmacy Times® interview, Emily Holcomb, PharmD, BCPS, ISMP Safe Medication Management Fellow, discussed her CPhT 2021 conference presentation regarding targeted medication safety best practices.
She talks about what targeted medication safety best practices is, what it is used for, and how it applies to pharmacy technicians.
Advertisement
Related to this article
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
4
Why Drug Dosing in Acute Kidney Injury Is So Hard to Get Right
5